IL113530A0 - Bifunctional protein preparation and use - Google Patents
Bifunctional protein preparation and useInfo
- Publication number
- IL113530A0 IL113530A0 IL11353095A IL11353095A IL113530A0 IL 113530 A0 IL113530 A0 IL 113530A0 IL 11353095 A IL11353095 A IL 11353095A IL 11353095 A IL11353095 A IL 11353095A IL 113530 A0 IL113530 A0 IL 113530A0
- Authority
- IL
- Israel
- Prior art keywords
- sub
- hinge region
- zeta
- bifunctional protein
- joined
- Prior art date
Links
- 230000001588 bifunctional effect Effects 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94810244 | 1994-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL113530A0 true IL113530A0 (en) | 1995-07-31 |
Family
ID=8218248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11353095A IL113530A0 (en) | 1994-05-02 | 1995-04-28 | Bifunctional protein preparation and use |
Country Status (18)
Country | Link |
---|---|
US (1) | US6984382B1 (fr) |
EP (1) | EP0758394B1 (fr) |
JP (1) | JP3742103B2 (fr) |
KR (1) | KR100373813B1 (fr) |
AT (1) | ATE228166T1 (fr) |
AU (1) | AU694222B2 (fr) |
CA (1) | CA2188422C (fr) |
DE (1) | DE69528894T2 (fr) |
DK (1) | DK0758394T3 (fr) |
ES (1) | ES2185705T3 (fr) |
FI (1) | FI119191B (fr) |
IL (1) | IL113530A0 (fr) |
NO (1) | NO316923B1 (fr) |
NZ (1) | NZ285395A (fr) |
PT (1) | PT758394E (fr) |
TW (1) | TW428026B (fr) |
WO (1) | WO1995030014A1 (fr) |
ZA (1) | ZA953440B (fr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU694222B2 (en) | 1994-05-02 | 1998-07-16 | Bernd Groner | Bifunctional protein, preparation and use |
WO1997024446A2 (fr) * | 1995-12-29 | 1997-07-10 | Chiron Corporation | Ligands de ciblage de vehicules pour l'apport de genes |
AU4373197A (en) * | 1996-09-19 | 1998-04-14 | Diagnocure Inc. | Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
DE10121113A1 (de) * | 2001-04-28 | 2002-10-31 | Gabriele Pecher | Genmodifizierte YT Zelllinie und ihre Verwendung |
DK2921500T3 (da) | 2004-07-10 | 2023-09-18 | The Institute For Cancer Res | Genetisk modificerede, humane, naturlige dræbercellelinjer |
US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
NI200800032A (es) | 2005-07-25 | 2009-03-23 | Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20 | |
MX2008015524A (es) * | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
US20100105136A1 (en) * | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
SI2132228T1 (sl) | 2008-04-11 | 2011-10-28 | Emergent Product Dev Seatle | CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
WO2011059836A2 (fr) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | Compositions de lymphocytes t déficientes en récepteurs de lymphocytes t |
EP3012268B1 (fr) | 2010-09-08 | 2017-11-15 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Recepteurs d'antigenes chimeriques comprenant une region charniere optimisee |
PL3214091T3 (pl) | 2010-12-09 | 2019-03-29 | The Trustees Of The University Of Pennsylvania | Zastosowanie komórek T modyfikowanych chimerycznymi receptorami antygenowymi do leczenia nowotworów |
WO2013033626A2 (fr) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Produits thérapeutiques ciblant un récepteur nkp30 |
EP2847223B1 (fr) | 2012-05-07 | 2019-03-27 | Trustees of Dartmouth College | Anticorps anti-b7-h6, protéines de fusion, et leurs procédés d'utilisation |
DK2958943T3 (da) | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
ES2814962T3 (es) | 2013-02-20 | 2021-03-29 | Novartis Ag | Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123 |
EP3623380A1 (fr) | 2013-03-15 | 2020-03-18 | Michael C. Milone | Ciblage de cellules cytotoxiques avec récepteurs chimériques pour immunothérapie adoptive |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
CA3225453A1 (fr) | 2013-12-19 | 2015-06-25 | Novartis Ag | Recepteurs antigeniques chimeriques de la mesotheline humaine et leurs utilisations |
US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
WO2015112626A1 (fr) | 2014-01-21 | 2015-07-30 | June Carl H | Capacité améliorée de présentation de l'antigène de lymphocytes t de récepteur d'antigène chimérique (car) par l'introduction conjointe de molécules de stimulation conjointe |
SG10202109752XA (en) | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
EP3172237A2 (fr) | 2014-07-21 | 2017-05-31 | Novartis AG | Traitement du cancer au moyen d'un récepteur d'antigène chimérique anti-bcma humanisé |
AU2015292755B2 (en) | 2014-07-21 | 2020-11-12 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
WO2016014535A1 (fr) | 2014-07-21 | 2016-01-28 | Novartis Ag | Traitement du cancer au moyen d'un récepteur d'antigènes chimériques cll-1 |
MY189028A (en) | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
AU2015317608B2 (en) | 2014-09-17 | 2021-03-11 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
CN114107424A (zh) | 2014-10-08 | 2022-03-01 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
IL303247A (en) | 2014-12-29 | 2023-07-01 | Novartis Ag | Methods for preparing cells expressing a chimeric receptor antigen |
WO2016115482A1 (fr) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Promoteurs de phosphoglycérate kinase 1 (pgk) et procédés d'utilisation pour l'expression d'un récepteur antigénique chimérique |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
SG11201708191XA (en) | 2015-04-08 | 2017-11-29 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
JP7114457B2 (ja) | 2015-04-17 | 2022-08-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法 |
TW201708538A (zh) | 2015-07-21 | 2017-03-01 | 諾華公司 | 改良免疫細胞之功效及擴展之方法 |
WO2017027392A1 (fr) | 2015-08-07 | 2017-02-16 | Novartis Ag | Traitement du cancer à l'aide des protéines de récepteur cd3 chimères |
US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
WO2017053469A2 (fr) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Polypeptides de liaison à cd3 |
EP3393504A1 (fr) | 2015-12-22 | 2018-10-31 | Novartis AG | Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse |
US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
CN110225927B (zh) | 2016-10-07 | 2024-01-12 | 诺华股份有限公司 | 用于治疗癌症的嵌合抗原受体 |
ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
EP3589295A4 (fr) | 2017-02-28 | 2020-11-04 | Endocyte, Inc. | Compositions et méthodes de thérapie par lymphocytes t car |
RU2019133280A (ru) | 2017-03-22 | 2021-04-22 | Новартис Аг | Композиции и способы для иммуноонкологии |
AU2019209428A1 (en) | 2018-01-22 | 2020-07-30 | Endocyte, Inc. | Methods of use for CAR T cells |
JP7438988B2 (ja) | 2018-06-13 | 2024-02-27 | ノバルティス アーゲー | Bcmaキメラ抗原受容体及びその使用 |
CN110627895B (zh) * | 2018-06-25 | 2021-03-23 | 北京大学 | 肺癌特异性tcr及其分析技术和应用 |
SG11202101849XA (en) | 2018-08-31 | 2021-03-30 | Invectys SA | Chimeric antigen receptors against multiple hla-g isoforms |
KR20220104217A (ko) | 2019-11-26 | 2022-07-26 | 노파르티스 아게 | Cd19 및 cd22 키메라 항원 수용체 및 이의 용도 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0260880A3 (fr) | 1986-09-11 | 1990-03-07 | Dana-Farber Cancer Institute, Inc. | Méthode de déclenchement de la cytotoxicité |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
FI105320B (fi) | 1988-04-04 | 2000-07-31 | Oncogen | Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa |
AU656544B2 (en) | 1990-10-31 | 1995-02-09 | Brigham And Women's Hospital | Genetic modification of endothelial cells |
KR100246529B1 (ko) * | 1990-12-14 | 2000-04-01 | 스티븐 에이. 서윈. 엠.디. | 수용체 관련된 신호 변환 경로를 위한 키메라 사슬 |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
AU662311B2 (en) * | 1991-02-05 | 1995-08-31 | Novartis Ag | Recombinant antibodies specific for a growth factor receptor |
FR2672901B1 (fr) | 1991-02-15 | 1994-09-30 | Immunotech Sa | Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant. |
WO1992015326A1 (fr) | 1991-02-27 | 1992-09-17 | The Regents Of The University Of California | Immunogenicite a mediation par complexe de ciblage |
NZ241855A (en) | 1991-03-07 | 1994-04-27 | Gen Hospital Corp | Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor |
US5939531A (en) | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
WO1993019163A1 (fr) * | 1992-03-18 | 1993-09-30 | Yeda Research And Development Co, Ltd. | Genes de recepteurs chimeres et cellules transformees au moyen desdits genes |
EP0565794A1 (fr) | 1992-04-14 | 1993-10-20 | British Biotech Pharmaceuticals Limited | Induction des réponses CTL |
AU694222B2 (en) | 1994-05-02 | 1998-07-16 | Bernd Groner | Bifunctional protein, preparation and use |
-
1995
- 1995-04-20 AU AU24469/95A patent/AU694222B2/en not_active Ceased
- 1995-04-20 KR KR1019960706165A patent/KR100373813B1/ko not_active IP Right Cessation
- 1995-04-20 CA CA2188422A patent/CA2188422C/fr not_active Expired - Lifetime
- 1995-04-20 AT AT95918576T patent/ATE228166T1/de active
- 1995-04-20 ES ES95918576T patent/ES2185705T3/es not_active Expired - Lifetime
- 1995-04-20 EP EP95918576A patent/EP0758394B1/fr not_active Expired - Lifetime
- 1995-04-20 WO PCT/EP1995/001494 patent/WO1995030014A1/fr active IP Right Grant
- 1995-04-20 NZ NZ285395A patent/NZ285395A/xx not_active IP Right Cessation
- 1995-04-20 JP JP52796595A patent/JP3742103B2/ja not_active Expired - Fee Related
- 1995-04-20 PT PT95918576T patent/PT758394E/pt unknown
- 1995-04-20 DK DK95918576T patent/DK0758394T3/da active
- 1995-04-20 DE DE69528894T patent/DE69528894T2/de not_active Expired - Lifetime
- 1995-04-24 TW TW084103999A patent/TW428026B/zh active
- 1995-04-28 ZA ZA953440A patent/ZA953440B/xx unknown
- 1995-04-28 IL IL11353095A patent/IL113530A0/xx not_active IP Right Cessation
-
1996
- 1996-10-25 FI FI964311A patent/FI119191B/fi not_active IP Right Cessation
- 1996-11-01 NO NO19964641A patent/NO316923B1/no not_active IP Right Cessation
-
2000
- 2000-06-19 US US09/596,774 patent/US6984382B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
FI964311A (fi) | 1996-10-25 |
TW428026B (en) | 2001-04-01 |
AU2446995A (en) | 1995-11-29 |
ZA953440B (en) | 1995-11-02 |
NO964641D0 (no) | 1996-11-01 |
DK0758394T3 (da) | 2003-03-03 |
JP3742103B2 (ja) | 2006-02-01 |
NO964641L (no) | 1996-11-01 |
ES2185705T3 (es) | 2003-05-01 |
CA2188422C (fr) | 2011-03-15 |
CA2188422A1 (fr) | 1995-11-09 |
NO316923B1 (no) | 2004-06-28 |
EP0758394B1 (fr) | 2002-11-20 |
DE69528894T2 (de) | 2003-03-27 |
US6984382B1 (en) | 2006-01-10 |
PT758394E (pt) | 2003-04-30 |
DE69528894D1 (de) | 2003-01-02 |
EP0758394A1 (fr) | 1997-02-19 |
NZ285395A (en) | 1998-10-28 |
AU694222B2 (en) | 1998-07-16 |
WO1995030014A1 (fr) | 1995-11-09 |
FI119191B (fi) | 2008-08-29 |
ATE228166T1 (de) | 2002-12-15 |
FI964311A0 (fi) | 1996-10-25 |
JPH09512176A (ja) | 1997-12-09 |
KR100373813B1 (ko) | 2003-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL113530A0 (en) | Bifunctional protein preparation and use | |
IL112390A0 (en) | A cell which expresses chimeric receptors, DNA and vectors encoding said receptors and pharmaceutical compositions containing the same | |
WO2000023573A3 (fr) | Cellules modifiees specifiques a la molecule cd20 et utilisation de ces dernieres pour l'immunotherapie cellulaires des malignites cd20?+¿ | |
KR100271382B1 (en) | Human receptor h4-1bb | |
NZ333915A (en) | Soluble monovalent and multivalent MHC class II fusion proteins | |
EP0757099A3 (fr) | Molécules CTLA4 mutées et leur utilisation | |
CA2110518A1 (fr) | Recepteur ctla4, proteines de fusion contenant ce recepteur et utilisations de ces dernieres | |
WO2002077029A3 (fr) | Cellules immunitaires specifiques a cd19 redirigees | |
NZ332598A (en) | Human BAS-1 protein, and use as an antagonist for modulating physiology or development of a cell | |
CA2312667A1 (fr) | Nouvelle cytokine | |
ES2093623T3 (es) | Receptores monovalentes y oligovalentes, bioespecificos y oligoespecificos, su preparacion y empleo. | |
HK1001464A1 (en) | Receptor on the surface of activated t-cells:acts-4 | |
KR927003847A (ko) | 수용체-결합된 신호 변환 경로를 위한 키메라 사슬 | |
NZ527297A (en) | Immunosuppression by blocking T cell co-stimulation signal 2 (B7/CD28 interaction) | |
GR3030415T3 (en) | Platelet activating factor antagonists. | |
AU3526689A (en) | Peptides that block the binding of hiv-1 to the cd4 receptor protein | |
AU4375493A (en) | Isolated protein receptors, antibodies which bind thereto, nucleic acid sequence coding therefor, and uses thereof | |
WO1996021028A3 (fr) | Recepteurs de lymphocytes t heterodimeres solubles et leurs anticorps | |
AU3283693A (en) | Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy | |
AU2525597A (en) | Monoclonal antibodies binding human growth hormone (hgh) | |
AU2002323894A1 (en) | Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use | |
WO2001042294A3 (fr) | Proteine transmembranaire clasp-4 | |
MX9801253A (es) | Proteinas de fusion de alergeno -xc032. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |